Primary aldosteronism: new answers, new questions

Research output: Contribution to journalArticleResearchpeer-review

Abstract

There have been 2, and possibly 3, major questions for primary aldosteronism (PA) answered at least in principle over the past 5 years. The first is that of somatic mutations underlying the majority of aldosterone producing adenomas. The second is the extension of our knowledge of the genetics of familial hypertension, and the third the role of renal intercalated cells in sodium homeostasis. New questions for the next 5 years include a single accepted confirmatory/exclusion test; standardisation of assays and cut-offs; alternatives to universal adrenal venous sampling; reclassification of low renin hypertension ; recognition of the extent of occult PA; inclusion of low-dose mineralocorticoid receptor antagonist in first-line therapy for hypertension; and finally, possible resolution of the aldosterone/inappropriate sodium status enigma at the heart of the cardiovascular damage in PA.
Original languageEnglish
Pages (from-to)935 - 940
Number of pages6
JournalHormone and Metabolic Research
Volume47
Issue number13
DOIs
Publication statusPublished - 2015

Cite this

@article{19da0f95b658489eb7f01103e502c81e,
title = "Primary aldosteronism: new answers, new questions",
abstract = "There have been 2, and possibly 3, major questions for primary aldosteronism (PA) answered at least in principle over the past 5 years. The first is that of somatic mutations underlying the majority of aldosterone producing adenomas. The second is the extension of our knowledge of the genetics of familial hypertension, and the third the role of renal intercalated cells in sodium homeostasis. New questions for the next 5 years include a single accepted confirmatory/exclusion test; standardisation of assays and cut-offs; alternatives to universal adrenal venous sampling; reclassification of low renin hypertension ; recognition of the extent of occult PA; inclusion of low-dose mineralocorticoid receptor antagonist in first-line therapy for hypertension; and finally, possible resolution of the aldosterone/inappropriate sodium status enigma at the heart of the cardiovascular damage in PA.",
author = "Funder, {John W}",
year = "2015",
doi = "10.1055/s-0035-1565182",
language = "English",
volume = "47",
pages = "935 -- 940",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Thieme Publishing",
number = "13",

}

Primary aldosteronism: new answers, new questions. / Funder, John W.

In: Hormone and Metabolic Research, Vol. 47, No. 13, 2015, p. 935 - 940.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Primary aldosteronism: new answers, new questions

AU - Funder, John W

PY - 2015

Y1 - 2015

N2 - There have been 2, and possibly 3, major questions for primary aldosteronism (PA) answered at least in principle over the past 5 years. The first is that of somatic mutations underlying the majority of aldosterone producing adenomas. The second is the extension of our knowledge of the genetics of familial hypertension, and the third the role of renal intercalated cells in sodium homeostasis. New questions for the next 5 years include a single accepted confirmatory/exclusion test; standardisation of assays and cut-offs; alternatives to universal adrenal venous sampling; reclassification of low renin hypertension ; recognition of the extent of occult PA; inclusion of low-dose mineralocorticoid receptor antagonist in first-line therapy for hypertension; and finally, possible resolution of the aldosterone/inappropriate sodium status enigma at the heart of the cardiovascular damage in PA.

AB - There have been 2, and possibly 3, major questions for primary aldosteronism (PA) answered at least in principle over the past 5 years. The first is that of somatic mutations underlying the majority of aldosterone producing adenomas. The second is the extension of our knowledge of the genetics of familial hypertension, and the third the role of renal intercalated cells in sodium homeostasis. New questions for the next 5 years include a single accepted confirmatory/exclusion test; standardisation of assays and cut-offs; alternatives to universal adrenal venous sampling; reclassification of low renin hypertension ; recognition of the extent of occult PA; inclusion of low-dose mineralocorticoid receptor antagonist in first-line therapy for hypertension; and finally, possible resolution of the aldosterone/inappropriate sodium status enigma at the heart of the cardiovascular damage in PA.

UR - http://www.ncbi.nlm.nih.gov/pubmed/26588848

U2 - 10.1055/s-0035-1565182

DO - 10.1055/s-0035-1565182

M3 - Article

VL - 47

SP - 935

EP - 940

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 13

ER -